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IMPORTANCE Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative
age-relatedmacular degeneration among Asian individuals. To our knowledge, there are no
large randomized clinical trials to evaluate intravitreal ranibizumab, with and without
verteporfin photodynamic therapy (vPDT), for the treatment of PCV.
OBJECTIVE To compare the efficacy and safety of combination therapy of ranibizumab and
vPDTwith ranibizumabmonotherapy in PCV.
DESIGN, SETTING, AND PARTICIPANTS A double-masked, multicenter randomized clinical trial
of 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading
Center using indocyanine green angiography was conducted between August 7, 2013, and
March 2, 2017.
INTERVENTIONS Participants were randomized 1:1 to ranibizumab, 0.5 mg, and vPDT
(n = 168; combination therapy group) or ranibizumab, 0.5 mg, and sham PDT (n = 154;
monotherapy group). All participants received 3 consecutive monthly ranibizumab injections,
followed by a pro re nata regimen. Participants also received vPDT/sham PDT on day 1,
followed by a pro re nata regimen based on the presence of active polyps.
MAIN OUTCOMES ANDMEASURES Step 1 assessedwhether combination therapywas
noninferior (5-letter margin) to monotherapy for change in best-corrected visual acuity from
baseline and superior in complete polyp regression. If noninferiority was established, step 2
assessed whether combination therapy was superior to monotherapymeasured by
best-corrected visual acuity change at month 12.
RESULTS Baseline demographics of the 322 participants were comparable between the
treatment groups. Mean (SD) age of the patients was 68.1 (8.8) years, and overall, 69.9% of
the patients were men. At baseline, the overall mean best-corrected visual acuity andmean
central subfield thickness were 61.1 letters and 413.3 μm, respectively. At 12 months, mean
improvement from baseline was 8.3 letters with combination therapy vs 5.1 letters with
monotherapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indicating that combination
therapymet the predefined criterion for noninferiority as well as being superior to
monotherapy (P = .01). Combination therapy was also superior to monotherapy in achieving
complete polyp regression at month 12 (69.3% vs 34.7%; P < .001). Over 12 months, the
combination therapy group received amedian of 4.0 ranibizumab injections compared with
7.0 in themonotherapy group. Vitreous hemorrhage was the only ocular serious adverse
event (combination therapy group, 1 [0.6%]; monotherapy group, 3 [2.0%]).
CONCLUSIONS AND RELEVANCE After 12months, combination therapy of ranibizumab plus
vPDTwas not only noninferior but also superior to ranibizumabmonotherapy in
best-corrected visual acuity and superior in complete polyp regression while requiring fewer
injections. Combination therapy should be considered for eyes with PCV.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01846273.
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P olypoidal choroidal vasculopathy (PCV) is an exuda-tive retinal disease characterized by an abnormal sub-retinal pigment epithelial networkof vessels of choroi-
dal origin, ending in aneurysmal dilatations, which appear as
spheroidal polyplike structures.1 Hemorrhage and exudation
from this vascular network can lead to chronic, multiple, re-
current serosanguineous detachments of the retinal pigment
epithelium and retina.1,2 Untreated, the long-term prognosis
of PCV is poor.3
The pathogenesis of PCV remains unclear; it was initially
considered a distinct abnormality of the inner choroidal
vasculature2;however, thehistopathologicalevidencesuggests
that PCV is a variant of type I or occult choroidal neovascular-
ization seen inneovascular age-relatedmacular degeneration
(nAMD), locatedaboveorwithin theBruchmembrane.4-6 Fur-
thermore, studies within the past decade show that systemic
andgenetic risk factors for PCVand typical nAMDappear tobe
fairly similar.7-9 Thus, PCV is considered one of the subtypes
of nAMD.1,10,11
Indocyanine green angiography (ICGA) is essential for ac-
curately diagnosing PCV, helping to visualize the hyperfluo-
rescent polypoidal lesions.10,12,13 In general, PCV is reported
to be more prevalent in certain racial/ethnic groups, espe-
cially inAsian individuals,where theproportionofPCVamong
nAMD cases varies from 22.3% to 61.6%.4,14,15 However, with
increased use of ICGA and advances in other diagnostic
techniques,12,13 a rise in the frequency of PCV diagnosis has
been observed across all patient populations.4,16-18
Theanti–vascular endothelial growth factor agent ranibiz-
umab, with or without verteporfin photodynamic therapy
(vPDT), has shownefficacy in improvingvisual outcomes and
diminishingpolypoidal lesions inpatientswithPCV.10,19,20The
EVERESTstudywasarandomizedclinical trial in61participants
that showed that combination therapywas significantly supe-
rior to ranibizumabmonotherapy inachievingcompletepolyp
regressionover6months.19Althoughbest-correctedvisualacu-
ity (BCVA)also improvedinparticipantstreatedwitheithercom-
bination therapyor ranibizumabmonotherapy, the studywas
notpowered tocompare theeffectsof these treatmentmodali-
ties on BCVA gains and did not evaluate results beyond 6
months.19 Therefore,weconducted the24-monthEVEREST II
trial to compare the long-term effect of combination therapy
vs ranibizumabmonotherapy in a large Asian patient popula-
tion with symptomatic macular PCV. Here, we report the 12-
month primary and secondary outcomes.
Methods
Study Design
TheEVERESTII trialwasa24-monthmulticenter, randomized,
double-masked study designed to compare the efficacy and
safety profile of ranibizumab, 0.5mg, and vPDT combination
therapywithranibizumab,0.5mg,monotherapy inparticipants
with symptomaticmacularPCVfromHongKong, Japan,South
Korea,Malaysia, Singapore, Taiwan, and Thailand. The study
was conducted in accordancewith theDeclarationofHelsinki
and Tripartite International Council on Harmonization Good
ClinicalPracticeGuidelinesandapplicable local regulations.The
studyprotocolwas reviewedandapprovedbyan independent
ethics committee or institutional reviewboard at each center.
All participants providedwritten informed consent. The trial
protocol and statistical analysis plan are available in
Supplement 1.
Participants
The study population consisted of treatment-naive partici-
pants 18years andolderwith symptomaticmacularPCV, asde-
fined by the presence of active macular polypoidal lesions on
ICGAandby thepresenceof serosanguineousmaculopathyon
color fundus photography and fluorescein angiography. The
presenceofPCVin1studyeyeandeligibility forenrollmentwere
confirmedby theCentralReadingCenter (Fundus ImageRead-
ing Centre, Singapore) using a standardized reading protocol
usingwell-defined grading criteria as in EVEREST.12,19 The eli-
gible BCVA letter score rangewas between 78 and 24 (approxi-
mately 20/32 to 20/320 Snellen equivalent), measured using
EarlyTreatmentDiabeticRetinopathyStudyvisualacuitycharts
at 4m following refraction.
Details of the patient inclusion and exclusion criteria are
listed in the eMethods in Supplement 2.
Randomization and Treatment
Participants,evaluatinginvestigators,visionexaminers,andCen-
tralReadingCentergradersweremaskedtothetreatment.Sepa-
rateunmaskedinvestigators (treatingphysicians)performedthe
treatments.Alleligibleparticipantswererandomized1:1 toeither
combination therapywith ranibizumab, 0.5mg, and standard
fluencevPDTorranibizumab,0.5mg,monotherapy(withsham
PDT). Randomization was balanced by site (eMethods in
Supplement 2).
Allparticipantswereassessedmonthly.An intravitreal ran-
ibizumab injection (0.5mg/0.05mL)wasadministeredonday
1 (baseline) and at months 1 and 2, followed by a pro re nata
(PRN) regimen according to the protocol-specific retreat-
ment criteria,withat least a28-day interval between2 ranibiz-
umab treatments (eMethods and eFigure 1 in Supplement 2).
On day 1, participants in the combination groupwere infused
with intravenous verteporfin (6 mg/m2), and those in the
Key Points
Question Are there any differences in treatment outcomes
between combination therapy with intravitreal ranibizumab and
verteporfin photodynamic therapy compared with ranibizumab
monotherapy in polypoidal choroidal vasculopathy?
Findings In themulticenter EVEREST II randomized clinical trial,
compared with ranibizumabmonotherapy, treatment of
polypoidal choroidal vasculopathy with ranibizumab plus
verteporfin photodynamic therapy resulted in greater visual acuity
improvement (8.3 vs 5.1 letters) with monotherapy and complete
resolution of lesions with fewer ranibizumab injections.
Meaning These data suggest ranibizumab plus verteporfin
photodynamic therapy should be considered for treatment of eyes
with polypoidal choroidal vasculopathy.
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monotherapy groupwere infusedwith 5%dextrose solution.
Fifteenminutes after the start of infusion, laser (light dose, 50
J/cm2; dose rate, 600mW/cm2; wavelength, 689 nm)was ap-
plied onto the whole lesions in the study eye for 83 seconds.
Photodynamic therapy tubingwas coveredwith foil or a blan-
ket. Thereafter, vPDTor shamPDTwasadministeredonaPRN
basis frommonth 3 onwards per the protocol-specific retreat-
ment criteria (eMethods and eFigure 1 in Supplement 2),with
at least a 3-month interval between2vPDTor shamPDT treat-
ments. As per protocol criteria, fellow eyes that developed
macular pathologies were appropriately treated (Trial Proto-
col in Supplement 1).
Study Objectives
Theprimary objectiveswere to demonstrate that combination
therapywas (1)noninferior toranibizumabmonotherapy inpar-
ticipantswithsymptomaticmacularPCVwithrespect tochange
in BCVA (Early Treatment Diabetic Retinopathy Study letters)
frombaselinetomonth12withapredefinednoninferioritymar-
gin of 5 letters and (2) superiorwith respect to complete polyp
regression as assessed by ICGA at month 12. Once this was es-
tablished, the next stepwas to show the superiority of combi-
nation therapy vs ranibizumab monotherapy with respect to
BCVAchange frombaseline tomonth 12. The secondary objec-
tives included additional functional and anatomical out-
comes, treatmentexposure, andsafetyandtolerability forboth
treatments up tomonth 12.
Efficacy Assessments
Efficacyassessments includedbothfunctional (BCVA)andmul-
timodal image (ICGA, fluorescein angiography, color fundus,
and spectral-domain optical coherence tomography) evalua-
tions of the study eye. Disease activitywas assessed based on
BCVA loss, spectral-domain optical coherence tomography,
ICGA, fluorescein angiography, and color fundus anomalies
(eMethods in Supplement 2).
Safety Assessments
Adverse events (AEs) were assessed at each visit.
Statistical Analysis
A sample size of 160 participants per treatment group was
estimated to appropriately power the prespecified primary
analysis,with the combinedpower to achieve a 1-sidednonin-
ferioritymarginof 5 letters between combination therapy and
ranibizumab monotherapy with respect to the BCVA change
frombaseline tomonth12, superioritywith respect tocomplete
polyp regression, and superioritywith respect toBCVAchange
frombaselineat the 1-sided levelofα = .025wasat least87.0%.
The primary efficacy objective was tested based on an
analysis of covariance model including treatment group as a
factor and (centered) baseline BCVA as a continuous variable
for testing noninferiority/superiority of BCVA change from
baseline and on a Fisher test to evaluate for superiority with
respect tocompletepolypregression (eMethods inSupplement
2). The multiple 1-sided α-level of .025 was to be maintained
by applying a sequentially rejecting multiple testing proce-
dure (steps 1 and 2).
Baselinedemographicsanddiseasecharacteristics arepre-
sented using descriptive statistics. The primary analysis was
conducted on the full analysis set (FAS) using the last obser-
vation carried forward approach for imputation of the miss-
ing data. The FAS comprised all participants who were as-
signed to a treatment regimen. The secondary analyses were
conducted on the study eye of participants in the FAS. The
safety analysis was descriptive and conducted on the safety
set that consistedof all participantswho received at least 1 ap-
plication of study treatment and had at least 1 postbaseline
safety assessment.
Results
Patient Disposition and Baseline Characteristics
In total, 322 participants were randomized to receive com-
bination therapy (n = 168) or ranibizumab monotherapy
(n = 154; Figure 1). Five participants without active polyps
were randomized in error before Central Reading Center
confirmation.
Baselinecharacteristicswerecomparablebetweengroups.
Overall, themean (SD) ageof participantswas68.1 (8.8) years,
and most participants were men (69.9%; Table). The mean
Figure 1. Patient Disposition (Randomized Set)
491 Total screened
169 Not randomized (34.4%)
due to screening failure
322 Patients with PCV enrolled
and randomized
158 Completed 12-month study
period (94.0%)
168 Randomized to receive
ranibizumab, 0.5 mg, + vPDT
154 Randomized to receive
ranibizumab, 0.5 mg
136 Completed 12-month study
period (88.3%)
10 Patients (6.0%) discontinued
study prior to month 12
4 Adverse events (2.4%)
1 Patient withdrew consent (0.6%)
1 Lost to follow-up (0.6%)
1 Administrative problems (0.6%)
1 Death (0.6%)
0 Disease progression
2 Protocol deviation (1.2%)
0 Physician’s decision
18 Patients (11.7%) discontinued
study prior to month 12
5 Adverse events (3.2%)
6 Patients withdrew consent (3.9%)
1 Lost to follow-up (0.6%)
0 Administrative problems
0 Death
1 Disease progression (0.6%)
3 Protocol deviation (1.9%)
2 Physician’s decision (1.3%)
Randomized set consisted of all randomized participants. Percentages are
based on the total number of participants in the randomized set in the
respective treatment groups. The 5 participants discontinued from the study
owing to protocol deviation were enrolled before the Central Reading Center
confirmed polypoidal choroidal vasculopathy (PCV) diagnosis. One of the 2
participants whom the physician decided to withdraw did not respond to
treatment and the primary investigator decided to change the treatment. In the
other case, there were no documented reasons but the participant did not
experience any adverse events. Spectral-domain optical coherence
tomography, color fundus photography, fluorescein angiography, and
indocyanine green angiography were assessed by the Central Reading Center.
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baseline BCVA letter score was similar between the combi-
nation (61.1 [approximate Snellen equivalent, 20/63]) and
monotherapy groups (61.2 [approximate Snellen equivalent,
20/63]; Table). Most study eyes had occult with no classic
component lesion types at baseline (Table). Overall, 294
participants completed the first 12 months of the study (158
in the combination arm and 136 in the monotherapy arm;
Figure 1).
Efficacy
At 12 months, mean improvement from baseline was 8.3
letters with combination therapy vs 5.1 letters with mono-
therapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indi-
cating that combination therapymet the predefined criterion
for noninferiority. Combination therapy was statistically su-
perior to ranibizumabmonotherapy in improving BCVA from
baseline at month 12 (8.3 vs 5.1 letters; P = .01, eTable 1 in
Supplement 2). Mean change in BCVA from baseline up to
month 12 is shown inFigure 2A. Sensitivity analysesusingdif-
ferent modeling methods and approaches for handling miss-
ing data and outlier values produced similar results (eTables
2-4 in Supplement 2).
At month 12, 24.5% of participants (n = 38) in the combi-
nation arm and 14.0% of participants (n = 19) in the mono-
therapy arm showed a significant BCVA gain of at least 15 let-
ters (P = .03; eFigure 2 in Supplement 2). At month 12, the
proportion of participants with BCVA at least 69 letters of the
study eye (approximately 20/40 Snellen equivalent) in-
creased from 32.7% at baseline to 69.0% in the combination
Table. Patient Demographics, Baseline Disease, and Ocular
Characteristics (Randomized Set)
Parameter
No. (%)a
Ranibizumab,
0.5 mg, + vPDT
(n = 168)
Ranibizumab,
0.5 mg
(n = 154)
Age, y
No. 168 154
Mean (SD) 68.0 (8.5) 68.2 (9.0)
Age category, y
<50 0 4 (2.6)
50-<65 57 (33.9) 53 (34.4)
65-<75 73 (43.5) 56 (36.4)
75-<85 33 (19.6) 34 (22.1)
≥85 5 (3.0) 7 (4.5)
Sex
Male 109 (64.9) 116 (75.3)
Female 59 (35.1) 38 (24.7)
Race/ethnicity
Chinese 64 (38.1) 59 (38.3)
Indian (Indian subcontinent) 3 (1.8) 2 (1.3)
Japanese 46 (27.4) 38 (24.7)
Other 55 (32.7) 55 (35.7)
BCVA score, letters
No. 168 153
Mean (SD) 61.1 (12.6) 61.2 (13.9)
Categorized BCVA letter score
(approximate Snellen equivalent)
<39 (Worse than 20/160) 8 (4.8) 11 (7.1)
39 -54 (20/160 to Worse than
20/80)
34 (20.2) 27 (17.5)
≥54 -<74) (20/80 to Worse than
20/32)
97 (57.7) 87 (56.5)
≥74 (20/32 or Better) 29 (17.3) 28 (18.2)
Missing 0 1 (0.6)
Central subfield thickness, μm
No. 159 149
Mean (SD) 415.9 (143.7) 410.4 (170.9)
Type of lesion, No. (%)
100% classic 2 (1.2) 1 (0.6)
Predominantly classic 2 (1.2) 0
Minimally classic 9 (5.4) 16 (10.4)
Occult with no classic component 139 (82.7) 124 (80.5)
Cannot grade 16 (9.5) 13 (8.4)
Presence of massive submacular
hemorrhage
No 147 (87.5) 135 (87.7)
Yes 19 (11.3) 15 (9.7)
Cannot grade 2 (1.2) 4 (2.6)
Presence of serosanguinous
hemorrhage
No 72 (42.9) 61 (39.6)
Yes 94 (56.0) 88 (57.1)
Cannot grade 2 (1.2) 5 (3.2)
Presence of polyps
No 2 (1.2) 3 (1.9)
Yes 166 (98.8) 151 (98.1)
Cannot grade 0 0
(continued)
Table. Patient Demographics, Baseline Disease, and Ocular
Characteristics (Randomized Set) (continued)
Parameter
No. (%)a
Ranibizumab,
0.5 mg, + vPDT
(n = 168)
Ranibizumab,
0.5 mg
(n = 154)
No. of polyps
0 0 0
1 24 (14.3) 34 (22.1)
2 32 (19.0) 33 (21.4)
3 32 (19.0) 23 (14.9)
4 22 (13.1) 19 (12.3)
≥5 56 (33.3) 42 (27.3)
Missing 2 (1.2) 3 (1.9)
Polyp size, mm2
No. 166 151
Mean (SD) 0.410 (0.426) 0.379 (0.331)
Presence of BVN
No 9 (5.4) 7 (4.5)
Yes 158 (94.0) 146 (94.8)
Cannot grade 1 (0.6) 1 (0.6)
BVN size, mm2
No. 158 146
Mean (SD) 3.140 (2.765) 2.614 (2.231)
Abbreviations: BCVA, best-corrected visual acuity; BVN, branching vascular
network.
a Percentages are based on total number of participants in the randomized set
in the respective treatment group.
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arm and from 40.8% at baseline to 58.8% in the mono-
therapy arm (Figure 2B).
Combination therapy showed statistically significant su-
periority to ranibizumab monotherapy in achieving com-
pletepolyp regression atmonth 12 as assessedby ICGA (69.3%
vs 34.7%; P < .001). The superiority of the combination arm
vs themonotherapy arm in achieving complete polyp regres-
sionwas consistent frommonths 3 to 12 (Figure 3). In the com-
bination therapy group, 51.6% of participants showed ab-
senceof leakageonfluoresceinangiographyatmonth12vs25%
in the monotherapy group (eFigure 3 in Supplement 2).
Themeanreduction inCSFTfrombaseline tomonth12was
greater in the combination arm than in themonotherapy arm
(least squares mean, −164.9 μm vs −113.4 μm, P < .001). In-
vestigator-assessedchange inCSFTof thestudyeye frombase-
line is illustrated in Figure 4A.
The proportion of participants with disease activity from
month 3 tomonth 11was lower in the combination arm than in
themonotherapyarm(month3, 26.4%vs60.7%andmonth 11,
20.5% vs 50.0%; Figure 4B). At month 12, serosanguineous
maculopathywas present in 14.8% of participants in the com-
binationgroup(n = 23)and in8.8%ofparticipants in themono-
therapygroup(n = 12),whereassubmacularhemorrhage(>4disc
areas) was reported in 1.3% of participants in the combination
group(n = 2)and0.7%ofparticipants inthemonotherapygroup
1). The anatomic outcomes can be clearly seen in an example
case provided (eFigure 4 in Supplement 2).
Treatment Exposure
Themean (median)numberof ranibizumab injections admin-
isteredup tomonth 12was5.2 (4) for combination therapyand
7.3 (7) for ranibizumabmonotherapy, respectively (eTable 5 in
Figure 3. Proportion of ParticipantsWith Complete Polyp Regression by
Study Visits up toMonth 12 in Full Analysis Set (FAS)
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Figure 2. Mean Change in Best-Corrected Visual Acuity (BCVA) From
Baseline toMonth 12 (Full Analysis Set)
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Figure 4. Mean Central Subfield Thickness (CSFT) Change
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Mean CSFT change from baseline to month 12, full analysis set (FAS) (A) and
proportion of participants with disease activity by visit (FAS) (B) as assessed by
the investigators. Number values indicate the total number of participants in
the FAS in the respective treatment group. Percentages are computed by
considering the total number of participants in the respective treatment group
who attended the specific visit as a denominator. vPDT indicates verteporfin
photodynamic therapy.
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Supplement 2). The difference in the log injection rates be-
tween the 2 groupswas statistically significant (ratio of injec-
tion rates [ranibizumab, 0.5mg,with vPDT/ranibizumab, 0.5
mg], 0.68; P < .001). Approximately 50.6% of participants
(n = 87) in the combination arm required 3 or 4 ranibizumab
injections vs 26.2% of participants (n = 39) in the mono-
therapyarm,while 32.2%ofparticipants (n = 48) in themono-
therapy arm required 10 to 12 injections over 12months com-
paredwith8.7%ofparticipants in thecombinationarm(n = 15)
(eFigure 5A in Supplement 2).
The mean (median) number of vPDT treatments in the
combination armwas 1.5 (1), and themean (median) number
of sham PDT treatments in the monotherapy arm was 2.3 (2)
(eTable 1 in Supplement 2). Overall, 61.0% of the participants
in the combination arm needed only the first vPDT at base-
line over the 12 months (eFigure 5B in Supplement 2).
Safety
Vitreous hemorrhage was the only serious ocular AE re-
ported in 1 patient in the combination arm (0.6%) and 3 pa-
tients in themonotherapyarm(2.0%) (eTable6 inSupplement
2). No cases of endophthalmitis or retinal break/detachment
were reported in either treatment group. Rates of nonocular
seriousAEswere comparable betweenboth treatment groups
(7.6%inthecombinationarmvs7.4%inthemonotherapyarm).
One patient from the combination group died of chronic ob-
structive pulmonary disease.
Ocular AEs of the study eye were reported in 26.7% of
participants in the combinationarm (n = 46) and25.5%ofpar-
ticipants in the monotherapy arm (n = 38) (eTable 7 in
Supplement 2). Themost commonAEswere intraocular pres-
sure increase (5.2% and 4.7%), retinal hemorrhage (3.5% and
0.7%), and conjunctivitis (1.7% and 3.4%) in the combination
and monotherapy groups, respectively. Nonocular AEs, re-
gardless of study drug relationship, were reported in 42.4%
(n = 73) and 37.6% (n = 56) of participants in the combination
andmonotherapy groups, respectively.
Discussion
The 12-month results of EVEREST II demonstrated that
ranibizumab in combination with vPDT was not only nonin-
ferior but also superior to ranibizumab monotherapy in
improving vision. In addition, combination therapy was
found to be superior to monotherapy in achieving complete
polyp regression. Most patients maintained or reached at
least 69 letters with both treatment modalities at month 12
(eFigure 6 in Supplement 2). Despite having high baseline
BCVA, participants achieved notable BCVA gains of 8.3 let-
ters and 5.1 letters in the combination and monotherapy
groups, respectively. Importantly, over 12 months, the
median number of ranibizumab injections was 4 in the com-
bination group compared with 7 in the monotherapy group.
This difference in intravitreal injections could be significant
in terms of cost-effectiveness in many countries.
Our study should be compared with the few prospective
PCVtrials in the literature. In the12-monthFUJISANstudy,par-
ticipants receiving combination therapy (either at baseline or
deferred) had a VA gain of 8.1 and 8.8 letters, respectively.21
In contrast, participants with PCV in the DRAGON study
showedaBCVAgainof 12.7 and9.4 letters over 12monthswith
monthly and PRN ranibizumabmonotherapy, respectively.22
The 12-month VA gains in the PLANET study, which assessed
fixed dosing of aflibercept in PCV participantswith andwith-
out rescue PDT, were reported to be 10.8 and 10.7 letters,
respectively.23 Differences in baseline BCVAacross the differ-
ent studies may account for the differences in BCVA gains
because poorer baseline BCVA is an important predictor of
superior numerical change in BCVA. The baseline BCVA letter
score for theranibizumabPRNmonotherapyarminEVERESTII
(61.2 [approximateSnellenequivalent, 20/63])washigher than
the baseline BCVA in the ranibizumab PRN arm in DRAGON
(54.6 [approximate Snellen equivalent, 20/80])22 and possi-
bly higher than in the aflibercept and sham rescue PDT arm
inPLANET (57.7).23 Importantly, therapeuticoutcomesmaybe
underrepresented by simply evaluating VA gains; other fac-
tors, suchasanatomical responses,polyp regression, andtreat-
mentburden,need tobe taken intoaccount. InEVEREST, com-
bination therapy was superior to ranibizumab monotherapy
in achieving complete polyp regression over 6months (77.8%
vs28.6%,P = .002).19 Similarly, inEVEREST II, completepolyp
regression ratesatmonths3,6, and12wereconsistentlyhigher
for combination therapy (71.4%, 71.3%, and 69.7%) vs
ranibizumab monotherapy (23.3%, 28.0%, and 33.8%). In
FUJISAN, the proportion of participants who showed resolu-
tion of polyps at month 12 was in broad agreement with
EVEREST II whether vPDT was given at baseline or deferred
(62.1% vs 54.8%, respectively, P = .53).21 Importantly, in
contrast to these, complete polyp regression rates at month
12 in PLANET were only 38.9% for the aflibercept and
sham PDT arm and 44.8% for the aflibercept and rescue PDT
arm.22 This is substantially lower than combination
therapy in EVEREST, EVEREST II, or FUJISAN and, in fact,
similar to the 12-month complete polyp regression rates in
the ranibizumab monotherapy arm in EVEREST II. Taken
together, these findings further strengthen the concept that
combination therapy achieves superior BCVA outcomes
than anti–vascular endothelial growth factor monotherapy
along with concomitant higher polyp closure rates.24,25 Fur-
thermore, the overall visual and anatomical outcomes of
EVEREST II, the largest combination therapy RCT to our
knowledge to date, are in concordance with the findings of
meta-analyses conducted in 2014 and 2016.16,24
In termsof treatmentburden, an increasing concern in the
anti–vascular endothelial growth factor therapyera, themean
number of ranibizumab injections required by the combina-
tion arm was significantly lower than the monotherapy arm.
Over 12months, 50.6%of the participants in the combination
arm required 3 to 4 ranibizumab injections, while only 8.7%
of participants in this group required 10 to 12 injections. This
reduction in injection numberwas similar to that observed in
other studies evaluating combination therapies for the PCV
treatment.21,26 In FUJISAN, initial vPDT therapy led to signifi-
cantly fewer additional ranibizumab treatments after the 3
loadingdosesvsdeferredvPDTtherapy.22Combinationtherapy
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may thus help reduce overall treatment burden and ulti-
mately PCV treatment costs.
In EVEREST II, both treatments showed a considerable
12-month reduction in the proportion of participants with
serosanguineous maculopathy and massive submacular
hemorrhage,25,26 thusallayingphysician fears aboutposttreat-
menthemorrhagewhenusingvPDTtotreatPCV.25-31Thesafety
profiles of both treatment groups were comparable and con-
sistent, with vitreous hemorrhage being the only ocular seri-
ousAEreportedduring 12monthsand lowratesof retinalhem-
orrhage in both treatment groups.
Polypoidal choroidal vasculopathy diagnosis has always
been challenging owing to its clinical and angiographic resem-
blance to other retinal pathologies, such as retinal angioma-
tous proliferation and central serous chorioretinopathy,18 po-
tentially leading to inappropriate therapy. For example, the
efficacy of anti–vascular endothelial growth factor therapy in
treatingcentralserouschorioretinopathyisunestablished.32Fur-
thermore, in some PCV cases, the polypsmay be ill-defined or
may have extensive bleeding, which renders diagnosis diffi-
cult. One of the strengths of EVEREST II was Central Reading
Center involvementduringscreening,usingwell-defined, strin-
gentcriteriamodifiedfromEVEREST.12,15Thisensuredthatonly
definite PCV cases were recruited. The EVEREST criteria have
also been validated in real-world settings.3
Limitations
The study had a few limitations. The administration of 3 ini-
tialmonthly injectionswaspresumptive because itwas based
on nAMD treatment guidelines, whichmay not apply to com-
bination treatment. Another potential limitation is that only
AsianparticipantswithPCVwere included,andtheresultsmay
be ethnospecific. Nevertheless, to our knowledge, no evi-
dence has suggested differential ethnic responses in PCV.
Conclusions
The 12-month EVEREST II results confirm that combination
treatmentwith ranibizumab and vPDT is effective in improv-
ing visionof participantswith symptomaticmacular PCV. Im-
portantly, combination of ranibizumab with vPDT also helps
to achieve complete polyp regression, a key clinical outcome
for PCV treatment. These functional and anatomical out-
comeswere achievedwith fewer ranibizumab injections over
12 months, thereby reducing treatment burden.
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